The Code, Part 3: It’s now easier than ever to peer into your own genetic code. But are all of the new companies out there offering you information about yourself that you can believe?
Diagnostics allow for the identification of cancer types and other crucial biomarkers, and are used right through from discovery to market.
The companies plan to develop a diagnostic version of the Illumina TruSight Oncology 500 assay to measure potentially predictive biomarkers, including Tumour Mutation Burden (TMB).
A literature review finds an increased risk of cancer, late-stage cancer, and mortality, with increased waiting time between a positive screening and start of diagnostic testing.
Researchers have proposed a radical change in the way Alzheimer’s disease is defined, focusing on biological changes in the body, rather than clinical symptoms such as memory loss and cognitive decline.
Use of one of a cancer treatment offered on the basis of biomarkers instead of tissue type is being restricted because of inaccurate, insensitive diagnostic tests.
There is, as of yet, no cure for Alzheimer’s, but a new blood test could open the door to new avenues in drug discovery.
A group of researchers hopes to improve the understanding of present-day ailments by looking at the very engine of evolution: natural selection in humans.
Material left out of common processes for sequencing genetic material in cancer tumours may actually carry important information about why only some people respond to immunotherapy.
Studies carried out at Emory University have shown that DNA methylation patterns in saliva appear to be more similar to patterns from the brain, than methylation in blood. Researcher Alicia Smith Associate Professor and Vice Chair for Research, Gynecology and Obstetrics at Emory University joins the discussion.
Brain differences related to the neurodevelopmental disorder Fragile X are visible well before a diagnosis, which typically happens at age three or later, new research indicates.
Researchers have identified nearly 200 mutations in non-coding DNA that play a role in cancer. Each mutation could represent a new cancer drug target.
Singlera Genomics, a non-invasive genetic diagnostics company that focuses on early-stage cancer detection, has secured a $60 million Series A+ financing.
Experts in medicine and law are urging the US to allow for the replacement of mutation-bearing mitochondria to prevent fatal illnesses in children.